JennyElsaBlauMD
Endocrinology • Gaithersburg, MDDiabetes, Lipid Metabolism
Senior Medical Director Early Clinical Development, CVRM Astra Zeneca Adjunct Associate Research Clinician Metabolic Disease Branch NIDDK
Dr. Blau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Medimmune Way
Gaithersburg, MD 20878
Education & Training
National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2012 - 2015
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2009 - 2012
Georgetown University School of MedicineClass of 2009
Certifications & Licensure
DC State Medical License 2011 - 2022
VA State Medical License 2012 - 2014- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- 332 citationsSGLT2 Inhibitors May Predispose to KetoacidosisSimeon I. Taylor, Jenny E Blau, Kristina I. Rother
The Journal of Clinical Endocrinology and Metabolism. 2015-06-18 - 60 citationsSGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risksSimeon I. Taylor, Jenny E Blau, Kristina I. Rother, Amber L. Beitelshees
The Lancet. Diabetes & Endocrinology. 2019-12-01 - 187 citationsPossible adverse effects of SGLT2 inhibitors on bone.Simeon I. Taylor, Jenny E Blau, Kristina I. Rother
The Lancet. Diabetes & Endocrinology. 2015-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
